Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application
Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application
DJ Bristol Myers Squibb's Opdivo, Yervoy Show Positive Phase 3 Results for Additional Application
DJ百時美施貴寶(Bristol Myers Squibb)的Opdivo，Yervoy展示了額外應用的積極第三階段結果
By Matt Grossman
馬特·格羅斯曼(Matt Grossman)著
Bristol Myers Squibb Co. said Thursday that a Phase 3 trial testing the use of its Opdivo and Yervoy medications to treat unresectable advanced or metastatic esophageal squamous cell carcinoma showed positive results.
百時美施貴寶公司(Bristol Myers Squibb Co.)週四説，一項測試其Opdivo和Yerway藥物治療無法切除的晚期或轉移性食管鱗癌的3期試驗結果呈陽性。
The trial tested the efficacy of two treatments: Opdivo plus chemotherapy, and Opdivo plus Yervoy.
這項試驗測試了兩種治療方法的療效：Opdivo加化療，和Opdivo加伊爾沃伊。
Opdivo plus chemotherapy met its primary and secondary endpoints of providing a benefit both to patients whose tumors express PD-L1, and in the all-randomized population. The combination also met its primary endpoint of progression-free survival by blinded independent central review in patients whose tumors express PD-L1.
Opdivo加化療達到了它的主要和次要終點，既為腫瘤表達PD-L1的患者提供了好處，也為所有隨機人羣提供了好處。通過對腫瘤表達PD-L1的患者進行盲目的獨立中心回顧，聯合治療也達到了無進展生存期的主要終點。
Opdivo plus Yervoy also demonstrated improvement in overall survival in patients whose tumors express PD-L1 and in the all-randomized population. It didn't meet the other primary endpoint of progression-free survival by BICR in patients whose tumors express PD-L1.
在腫瘤表達PD-L1的患者和所有隨機人羣中，Opdivo Plus Yervoy也顯示出總體存活率的改善。在腫瘤表達PD-L1的患者中，BICR沒有達到無進展生存期的另一個主要終點。
The drugs' safety profiles were consistent with prior research, the company said.
該公司表示，這些藥物的安全性概況與之前的研究一致。
Dr. Ian Waxman, Bristol Myers Squibb's development lead for gastrointestinal cancers, said the results could lead to new treatment options for patients with esophageal cancer.
百時美施貴寶(Bristol Myers Squibb)胃腸道癌症開發負責人伊恩·韋克斯曼(Ian Waxman)博士表示，這一結果可能會為食道癌患者帶來新的治療選擇。
Write to Matt Grossman at matt.grossman@wsj.com
寫信給馬特·格羅斯曼(Matt Grossman)，電子郵件：matt.grossman@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
April 08, 2021 07:28 ET (11:28 GMT)
2021年4月8日07：28美國東部時間(格林尼治標準時間11：28)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。